Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 2.475 EUR 0.61% Market Closed
Market Cap: 215.1m EUR
Have any thoughts about
Inventiva SA?
Write Note

P/OCF
Price to OCF

-2.6
Current
-5.9
Median
23.4
Industry
Higher than median
Lower than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
-2.6
=
Market Cap
215.1m EUR
/
Operating Cash Flow
-81.6m EUR
All Countries
Close
Market Cap P/OCF
FR
Inventiva SA
PAR:IVA
215.1m EUR -2.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -236 050.3
US
Abbvie Inc
NYSE:ABBV
300.2B USD 18.2
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 21.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD -135.5
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 11.4
US
Epizyme Inc
F:EPE
94.1B EUR -476.6
AU
CSL Ltd
ASX:CSL
137.3B AUD 32.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 20.7
US
Seagen Inc
F:SGT
39.3B EUR -76.9
NL
argenx SE
XBRU:ARGX
34.1B EUR -138.6
 
FR
Inventiva SA
PAR:IVA
Average P/OCF: 20.9
Negative Multiple: -2.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -236 050.3
US
Abbvie Inc
NYSE:ABBV
18.2
US
Amgen Inc
NASDAQ:AMGN
21.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -135.5
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -476.6
AU
CSL Ltd
ASX:CSL
32.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
20.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -76.9
NL
argenx SE
XBRU:ARGX
Negative Multiple: -138.6

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A

See Also

Discover More